Oncology
Final Analysis of the Phase 1 First‑in‑Human Study of Erda-iDRS, an Erdafitinib Intravesical Drug-Releasing System, in Patients With Non–Muscle‑Invasive Bladder Cancer Harboring Select FGFR Alterations
Connect with us
Connect with us
Would you like to clear and leave your conversation? Message history will be lost.